Myriad Genetics (MYGN) Current Leases (2019 - 2026)

Myriad Genetics (MYGN) has reported Current Leases for 8 consecutive years, with $7.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 34.86% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 34.86% YoY), while the FY2025 annual figure was $6.9 million, down 46.09% from the prior year.
• Current Leases improved to $7.1 million in Q1 2026 per MYGN's latest filing, from $6.9 million in the prior quarter.
• Across five years, Current Leases topped out at $17.8 million in Q3 2023 and bottomed at $6.9 million in Q4 2025.
• Historically, Current Leases has averaged $12.7 million across 5 years, with a median of $13.4 million in 2022.
• Annual changes were most pronounced in 2023 — Current Leases increased 27.82% — and 2025, when it plunged 46.09%.
• Myriad Genetics' Current Leases stood at $14.1 million in 2022, then rose by 14.89% to $16.2 million in 2023, then decreased by 20.99% to $12.8 million in 2024, then slumped by 46.09% to $6.9 million in 2025, then gained by 2.9% to $7.1 million in 2026.
• Business Quant data shows MYGN's Current Leases at $7.1 million in Q1 2026, $6.9 million in Q4 2025, and $7.9 million in Q3 2025.